Consumer medicine information

Dexamethasone Viatris

Dexamethasone phosphate

BRAND INFORMATION

Brand name

Dexamethasone Viatris

Active ingredient

Dexamethasone phosphate

Schedule

SUMMARY CMI

DEXAMETHASONE VIATRIS^®

Consumer Medicine Information (CMI) summary

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist.

1. Why am I being given DEXAMETHASONE VIATRIS?

DEXAMETHASONE VIATRIS contains the active ingredient dexamethasone phosphate (as sodium). Dexamethasone phosphate (as sodium) is a glucocorticoid and belongs to a group of medicines called corticosteroids. It may be used to treat an inactive or underactive adrenal gland or to treat a number of different diseases such as certain immune disorders and skin problems, asthma or arthritis. Corticosteroids reduce inflammation, one of the body's reactions to injury. Except for its use in the treatment of underactive adrenal glands, dexamethasone phosphate (as sodium) does not cure disease; it treats the symptoms. For more information, see Section 1. Why am I being given DEXAMETHASONE VIATRIS? in the full CMI.

2. What should I know before I am given DEXAMETHASONE VIATRIS?

Do not use if you have ever had an allergic reaction to DEXAMETHASONE VIATRIS or any of the ingredients listed at the end of the CMI.

Talk to your doctor if you have any other medical conditions, take any other medicines, or are pregnant or plan to become pregnant or are breastfeeding.

For more information, see Section 2. What should I know before I am given DEXAMETHASONE VIATRIS? in the full CMI.

3. What if I am taking other medicines?

Some medicines may interfere with DEXAMETHASONE VIATRIS and affect how it works.

A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI.

4. How am I given DEXAMETHASONE VIATRIS?

DEXAMETHASONE VIATRIS is given as a slow injection or infusion (intravenous drip) into the veins. It may also be given as an injection into an injured muscle or joint. It may be given as a course of injections or as a single dose. DEXAMETHASONE VIATRIS injection should only be given by a doctor or nurse who will decide the correct dose depending upon the condition being treated, and other factors such as your weight.

More instructions can be found in Section 4. How am I given DEXAMETHASONE VIATRIS? in the full CMI.

5. What should I know while I am being given DEXAMETHASONE VIATRIS?

Things you should do	Remind any doctor, dentist or pharmacist you visit that you have been given DEXAMETHASONE VIATRIS if you: - plan to have surgery that requires a general anaesthetic - become pregnant while you are being treated with DEXAMETHASONE VIATRIS - get an infection while being treated with this medicine.
Driving or using machines	Be careful driving or operating machinery while being treated with DEXAMETHASONE VIATRIS, as it may cause dizziness and blurred vision in some people.
Drinking alcohol	If you drink alcohol while being treated with DEXAMETHASONE VIATRIS, you may experience dizziness
Looking after your medicine	DEXAMETHASONE VIATRIS will usually be stored in the pharmacy or on the ward, in a cool dry place, protected from light, where the temperature stays below 25°C.

For more information, see Section 5. What should I know while I am being given DEXAMETHASONE VIATRIS? in the full CMI.

6. Are there any side effects?

Dexamethasone phosphate (as sodium) may cause allergic reaction such as rash, itching or hives on the skin; swelling of the face, lips, tongue or other parts of the body; shortness of breath, wheezing or difficulty breathing. For more information, including what to do if you have any side effects, see Section 6. Are there any side effects? in the full CMI.

FULL CMI

DEXAMETHASONE VIATRIS^®

Active ingredient(s): Dexamethasone Phosphate (as sodium)

Consumer Medicine Information (CMI)

This leaflet provides important information about given DEXAMETHASONE VIATRIS injection. You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about given DEXAMETHASONE VIATRIS.

Where to find information in this leaflet:

1. Why am I being given DEXAMETHASONE VIATRIS?
2. What should I know before I am giben DEXAMETHASONE VIATRIS?
3. What if I am taking other medicines?
4. How am I given DEXAMETHASONE VIATRIS?
5. What should I know while I am being given DEXAMETHASONE VIATRIS?
6. Are there any side effects?
7. Product details

1. Why am being given DEXAMETHASONE VIATRIS?

DEXAMETHASONE VIATRIS contains the active ingredient dexamethasone phosphate (as sodium). DEXAMETHASONE VIATRIS is a glucocorticoid and belongs to a group of medicines called corticosteroids.

DEXAMETHASONE VIATRIS is used to treat an inactive or underactive adrenal gland or to treat a number of different diseases such as certain immune disorders, skin problems, asthma or arthritis.

Corticosteroids reduce inflammation, one of the body's reactions to injury.

Except for its use in the treatment of an underactive adrenal gland, DEXAMETHASONE VIATRIS does not cure disease; it treats the symptoms.

Ask your doctor if you have any questions about why this medicine has been prescribed for you.

Your doctor may have prescribed it for another reason.

This medicine is not addictive.

2. What should I know before I am given DEXAMETHASONE VIATRIS?

Warnings

You should not be given DEXAMETHASONE VIATRIS if:

you are allergic to dexamethasone sodium phosphate, or any of the ingredients listed at the end of this leaflet.

Some of the symptoms of an allergic reaction may include:

shortness of breath, wheezing or difficulty breathing, swelling of the face, lips, tongue or other parts of the body, rash, itching or hives on the skin

Always check the ingredients to make sure you can use this medicine.
an internal fungal infection or any other infection
recently been given a live vaccine unless you are being given this medicine for replacement therapy
myasthenia gravis, a muscle wasting disease
a stomach (peptic) ulcer
osteoporosis (weak or brittle bones)
have a severe mental health condition

Check with your doctor if you:

diabetes, a condition in which the level of sugar in the blood is too high
any current or recent infections
heart failure or a recent heart attack
kidney disease
liver disease
thyroid disease
inflammation of the bowel wall or other bowel problems
high blood pressure
eye diseases, including glaucoma or a family history of glaucoma, including infections, ulcers or allergies
muscle disease or injury
mental illness
epilepsy, seizures or convulsions, migraine
Cushing's disease, a condition where there is too much cortisol
a stomach ulcer
intestinal disease
osteoporosis (weak or brittle bones)
take any medicines for any other condition
myasthenia gravis, a muscle wasting disease
presence of bacteria in the bloodstream
unstable joints
infection at the injection site
latent tuberculosis, where you have tuberculosis bacteria in your body but do not feel sick
chicken pox or measles, or have been exposed to these recently
suspected or identified pheochromocytoma, which are tumours growing on part of your kidneys
suspected or identified pheochromocytoma, which are tumours growing on part of your kidneys
been diagnosed with Acute Respiratory Disease Syndrome (ARDS) for over 2 weeks
you have suffered a head injury or stroke
pre-eclampsia or fluid retention.

During treatment, you may be at risk of developing certain side effects. It is important you understand these risks and how to monitor for them. See additional information under Section 6. Are there any side effects?

Pregnancy and breastfeeding

Check with your doctor if you are pregnant or intend to become pregnant.

Like most corticosteroid medicines, dexamethasone is not generally recommended for use during pregnancy.

Talk to your doctor if you are breastfeeding or intend to breastfeed.

The active ingredient in DEXAMETHASONE VIATRIS may pass into breast milk and there is a possibility that your baby may be affected.

Tell your doctor or pharmacist if you have received any vaccinations recently.

3. What if I am taking other medicines?

Tell your doctor or pharmacist if you are taking any other medicines, including any medicines, vitamins or supplements that you buy without a prescription from your pharmacy, supermarket or health food shop.

Some medicines may interfere with DEXAMETHASONE VIATRIS and affect how it works.

These include:

barbiturates, carbamazepine or phenytoin, medicines used to treat epilepsy
aspirin and other non-steroidal anti-inflammatory medicines, especially phenylbutazone
insulin or other medicines for the control of blood sugar
estrogens and other oral contraceptives
anti-thyroid medicines used to treat an over active thyroid gland
fluid tablets (known as diuretics), particularly furosemide (frusemide) and thiazides or other medicines affecting the kidneys
anticoagulant medicines (medicines to prevent blood clots), such as warfarin or heparin
any recent vaccinations or immunisations
ciclosporin, a medicine used to prevent transplant rejection
rifabutin, rifampicin, amphotericin or vancomycin, medicines used to treat infections
ritonavir, a medicine used in the treatment of HIV/AIDS
ketoconazole, a medicine used to treat fungal infections
digoxin, a medicine used to treat heart conditions
aminoglutethimide, a hormone used to treat breast cancer
daunorubicin or doxorubicin, a medicine used to treat cancer
salbutamol, salmeterol, medicines used to treat asthma
some medicines used in the treatment of heartburn and indigestion
doxapram, a medicine used to treat chronic obstructive pulmonary disease
glycopyrrolate, a medicine used to dry up secretions or saliva.

These medicines may be affected by DEXAMETHASONE VIATRIS or may affect how well it works. You may need different amounts of your medicines, or you may need to take different medicines.

Check with your doctor or pharmacist if you are not sure about what medicines, vitamins or supplements you are taking and if these affect DEXAMETHASONE VIATRIS.

4. How am I given DEXAMETHASONE VIATRIS?

How much DEXAMETHASONE VIATRIS is given

The dose of DEXAMETHASONE VIATRIS is variable, depending on the condition being treated. It may be given as a course of injections or as a single dose.

Your doctor will determine the dose you will receive.

The dose depends on your condition and other factors, such as your weight.

As soon as an improvement in your condition is noticed, the dosage should be adjusted to the minimum required to control your symptoms.

As your doctor will give you the injection they will determine when it is given to you.

Your doctor will determine how long you will take this medicine for.

How is DEXAMETHASONE VIATRIS given

DEXAMETHASONE VIATRIS is given as a slow injection or infusion (intravenous drip) into the veins. It may also be given as an injection into an injured muscle or joint.

DEXAMETHASONE VIATRIS is an injection which is given to you by a doctor or nurse.

If you are given too much DEXAMETHASONE VIATRIS

As DEXAMETHASONE VIATRIS will most likely be given to you in hospital under the supervision of your doctor it is very unlikely that you will receive too much.

However, if you experience severe side effects tell your doctor or nurse immediately, or if you are not already in hospital go to Accident and Emergency at the nearest hospital or immediately contact the Poisons Information Centre for advice on overdose (Call 13 11 26).

You should do this even if there are no signs of discomfort or poisoning.

Symptoms of an overdose may include some of the side effects listed below 6. Are there any side effects including swelling of the limbs, sore stomach or altered mental state.

You may need urgent medical attention.

5. What should I know while being given DEXAMETHASONE VIATRIS?

Things you should do

If you are about to be started on any new medicine, remind your doctor and pharmacist that you are being given DEXAMETHASONE VIATRIS.

Tell any other doctors, dentists and pharmacists who treat you that you are being given this medicine.

If you are going to have surgery, tell the surgeon or anaesthetist that you are being given this medicine.

It may affect other medicines used during surgery.

If you become pregnant while you are being given this medicine, tell your doctor immediately.

Tell your doctor immediately if you get an infection whilst you are being given this medicine.

Like most corticosteroid medicine, dexamethasone may hide the symptoms of an infection.

Things you should not do

If you have been given DEXAMETHASONE VIATRIS for a painful or inflamed joint, you should be careful not to overuse the joint if the inflammation is still present.

Driving or using machines

Be careful before you drive or use any machines or tools until you know how DEXAMETHASONE VIATRIS affects you.

As with other corticosteroid medicines, dexamethasone may cause dizziness and blurred vision in some people.

If you have any of these symptoms, do not drive, operate machinery or do anything else that could be dangerous.

Drinking alcohol

Tell your doctor if you drink alcohol.

If you drink alcohol, dizziness may be worse.

Looking after your medicine

This medicine will usually be stored in the hospital pharmacy or on the ward, in a cool, dry place protected from light where the temperature stays below 25°C.

Keep it where young children cannot reach it.

When to discard your medicine

DEXAMETHASONE VIATRIS will be opened for use on you. It will be used only once and then it will be discarded. It will never be stored after it is opened nor used for more than one person.

Getting rid of any unwanted medicine

Any unwanted medicine will be disposed of in safe manner by our doctor, nurse or pharmacist.

6. Are there any side effects?

All medicines can have side effects. If you do experience any side effects, most of them are minor and temporary. However, some side effects may need medical attention.

See the information below and, if you need to, ask your doctor, nurse or pharmacist if you have any further questions about side effects.

If you are over 65 years of age you may have an increased chance of getting side effects.

If you only receive one or two doses of this medicine, side effects are rarer.

Less serious side effects

Less serious side effects	What to do
nausea and vomiting 'gas' or abdominal bloating bad taste in the mouth menstrual irregularity weight gain fluid retention increased body hair bruising easily wounds that take a long time to heal muscular weakness headache dizziness thin, fragile skin acne sleep disturbances reduced growth in children blurred vision fungal infection and being susceptible to other kinds of infections.	Speak to your doctor if you have any of these less serious side effects and they worry you.

Serious side effects

Serious side effects

What to do

signs of an allergic reaction such as a rash, itching or hives on the skin, swelling of the face, lips, tongue or other parts of the body, shortness of breath, wheezing or difficulty breathing
severe stomach pain
blood in the faeces
irregular heartbeat
changes in vision
changes in mood or sleep patterns
joint pain or broken bones
breakdown of weight-bearing joints (Charcot-like arthropathy)
tendon rupture
seizures or convulsions
signs of infection

Call your doctor straight away, or go straight to the Emergency Department at your nearest hospital if you notice any of these serious side effects.

Tell your doctor or nurse if you notice anything else that may be making you feel unwell.

Other side effects not listed here may occur in some people.

The above list includes serious side effects that may require medical attention. Serious side effects are rare.

Reporting side effects

After you have received medical advice for any side effects you experience, you can report side effects to the Therapeutic Goods Administration online at www.tga.gov.au/reporting-problems. By reporting side effects, you can help provide more information on the safety of this medicine.

Always make sure you speak to your doctor or pharmacist before you decide to stop taking any of your medicines.

7. Product details

This medicine is only available with a doctor's prescription.

What DEXAMETHASONE VIATRIS contains

Active ingredient (main ingredient)	Dexamethasone phosphate (as sodium)
Other ingredients (inactive ingredients)	sodium citrate creatine water for injections

Do not take this medicine if you are allergic to any of these ingredients.

What DEXAMETHASONE VIATRIS looks like

DEXAMETHASONE VIATRIS is a clear, colourless solution, free from visible particulate matter and packaged in a 2 mL amber vial with rubber stopper and aluminium seal.

This medicine is available in packs of 5 vials.

DEXAMETHASONE VIATRIS 4 mg/1 mL ampoule - AUST R 163200

DEXAMETHASONE VIATRIS 8 mg/2 mL ampoule - AUST R 163199

Who distributes DEXAMETHASONE VIATRIS

Alphapharm Pty Ltd trading as Viatris
Level 1, 30 The Bond
30-34 Hickson Road
Millers Point NSW 2000
www.viatris.com.au
Phone: 1800 274 276

This leaflet was prepared in July 2023.

DEXAMETHASONE VIATRIS_cmi\Jul23/00

Published by MIMS September 2023

BRAND INFORMATION

Brand name

Dexamethasone Viatris

Active ingredient

Dexamethasone phosphate

Schedule

1 Name of Medicine

Dexamethasone sodium phosphate.

2 Qualitative and Quantitative Composition

Each mL of Dexamethasone Viatris injection contains dexamethasone sodium phosphate 4.4 mg (equivalent to 4 mg dexamethasone phosphate) as the active ingredient.
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Solution for injection.
Dexamethasone Viatris is a clear, colourless solution, free from visible particulate matter and packaged in a 2 mL amber vial with rubber stopper and aluminium seal.

4 Clinical Particulars

4.1 Therapeutic Indications

Replacement therapy.

Adrenocortical insufficiency.

Dexamethasone has predominantly glucocorticoid activity and, therefore, is not a complete replacement therapy in cases of adrenocortical insufficiency. Dexamethasone should be supplemented with salt and/or a mineralocorticoid, such as deoxycorticosterone. When so supplemented, dexamethasone is indicated in the following:
Acute adrenocortical insufficiency - Addison's disease; bilateral adrenalectomy;
Relative adrenocortical insufficiency - Prolonged administration of adrenocortical steroids can produce dormancy of the adrenal cortex. The reduced secretory capacity gives rise to a state of relative adrenocortical insufficiency which persists for a varying length of time after therapy is discontinued. Should a patient be subjected to sudden stress during this period of reduced secretion (for up to two years after therapy has ceased) the steroid output may not be adequate. Steroid therapy should, therefore, be reinstituted to help cope with stress such as that associated with surgery, trauma, burns or severe infections where specific antibiotic therapy is available;
Primary and secondary adrenocortical insufficiency.

Disease therapy.

Dexamethasone is indicated for therapy of the following diseases:

1. Collagen diseases.

Systemic lupus erythematosus, polyarteritis nodosa, dermatomyositis, giant cell arteritis, adjunctive therapy for short-term administration during an acute episode or exacerbation, acute rheumatic carditis during an exacerbation or as maintenance therapy.

2. Pulmonary disorders.

Status asthmaticus, chronic asthma, sarcoidosis, respiratory insufficiency.

3. Blood disorders.

Leukaemia, idiopathic thrombocytopaenic purpura in adults, acquired (autoimmune) haemolytic anaemia.

4. Rheumatic diseases.

Rheumatoid arthritis, osteoarthritis, adjunctive therapy for short-term administration during an acute episode or exacerbation of rheumatoid arthritis or osteoarthritis.

5. Skin diseases.

Psoriasis, erythema multiforme, pemphigus, neutrophilic dermatitis, localised neurodermatitis, exfoliative dermatitis, sarcoidosis of skin, severe seborrhoeic dermatitis, contact dermatitis.

6. Gastrointestinal disorders.

Ulcerative colitis, regional enteritis.

7. Oedema.

Cerebral oedema associated with primary or metastatic brain tumours, neurosurgery or stroke, oedema associated with acute non-infectious laryngospasm (or laryngitis).

8. Eye disorders.

Allergic conjunctivitis, keratitis, allergic corneal marginal ulcers, chorioretinitis, optic neuritis, anterior ischaemic optic neuropathy.

9. Neoplastic states.

Cerebral neoplasms, hypercalcaemia associated with cancer, leukaemias and lymphomas in adults, acute leukaemia in children.

10. Endocrine disorders.

Adrenal insufficiency.

Preoperative and postoperative support.

Dexamethasone may be used in any surgical procedure when the adrenocortical reserve is doubtful. This includes the treatment of shock due to excessive blood loss during surgery.

Shock.

Dexamethasone may be used as an adjunct in the treatment of shock. See Section 4.2 Dose and Method of Administration. Dexamethasone should not be used as a substitute for normal shock therapy.

4.2 Dose and Method of Administration

Dexamethasone Viatris may be administered intravenously or intramuscularly for systemic effect, or as an intrasynovial or soft tissue injection for local effect.
Dosage of dexamethasone sodium phosphate is usually expressed in terms of dexamethasone phosphate.
For single patient use. Use once only and discard any residue.
Dosage requirements are variable and must be individualised on the basis of the disease being treated and patient response.

Intravenous and intramuscular administration.

Intravenous or intramuscular dosage usually ranges from 0.5 to 24 mg of dexamethasone phosphate daily. The duration of therapy is dependent on the clinical response of the patient and as soon as improvement is indicated, the dosage should be adjusted to the minimum required to maintain the desired clinical response. Withdrawal of the drug on completion of therapy should be gradual.
Parenteral dexamethasone is generally reserved for patients who are unable to take the drug orally or for use in an emergency situation.

Shock (of haemorrhagic, traumatic or surgical origin).

The usual dose for the treatment of shock is 2 to 6 mg/kg bodyweight as a single intravenous injection.
This may be repeated in two to six hours if shock persists.
An alternative regimen of 20 mg by intravenous injection initially, followed by continuous intravenous infusion of 3 mg/kg bodyweight per 24 hours, has been suggested. If required for intravenous infusion, Dexamethasone Viatris may be diluted with glucose or sodium chloride injection. High dose therapy should be continued only until the patient's condition has stabilised and usually for no longer than 48 to 72 hours.
To avoid microbial contamination hazards, infusion should be commenced as soon as practicable after preparation of the mixture and, if storage is necessary, store solution at 2°C to 8°C. Infusion should be completed within 24 hours of preparation of the solution and any residue discarded.

Warning.

Further diluted solutions which are not clear, or which show evidence of particulate matter contamination, should be discarded.

Cerebral oedema.

The treatment schedule and route of administration should reflect the severity and aetiology of the cerebral oedema. Treatment needs to be tailored to the individual response. An initial dose of 10 mg intravenously followed by 4 mg intramuscularly every six hours until the symptoms of oedema subside (usually after 12 to 24 hours). After two to four days the dosage should be reduced and gradually stopped over a period of five to seven days. Patients with cerebral malignancy may require maintenance therapy with doses of 2 mg intramuscularly or intravenously two to three times daily.
High doses of dexamethasone may be used to initiate short-term intensive therapy for acute cerebral oedema. Following an initial high loading dose, the dose is scaled down over the seven to ten-day period of intensive therapy and subsequently reduced to zero over the next seven to ten days (see Table 1 for high dose schedule).

Intrasynovial and soft tissue injections.

Dosage varies with the degree of inflammation and the size and location of the affected area. Injections may be repeated from once every three to five days (e.g. for bursae) to once every two to three weeks (for joints). Frequent intra-articular injection may result in damage to joint tissues (see Table 2 for dosages).

4.3 Contraindications

Administration of Dexamethasone Viatris is contraindicated in the following cases:
Systemic fungal infections or other systemic infections unless specific anti-infective therapy is given (see Section 4.4 Special Warnings and Precautions for Use).
Hypersensitivity to dexamethasone or other corticosteroids or to any component of the injection.
Administration of live virus vaccines (see Section 4.4 Special Warnings and Precautions for Use).
In patients with myasthenia gravis, peptic ulcer, osteoporosis or psychoses.
Bacteraemia.
Unstable joints.
Infection at the injection site e.g septic arthritis resulting from gonorrhoea or tuberculosis.

4.4 Special Warnings and Precautions for Use

In post marketing experience, tumour lysis syndrome (TLS) has been reported in patients with haematological malignancies following the use of dexamethasone alone or in combination with other chemotherapeutic agents. Patients at high risk of TLS, such as patients with high proliferative rate, high tumour burden and high sensitivity to cytotoxic agents, should be monitored closely and appropriate precaution taken.
Corticosteroids may increase susceptibility to or mask the symptoms of infection, and therefore should be used with caution in patients with systemic infections. Chicken pox, measles and other infections can have a more serious or even fatal effect in non-immune children or adults on corticosteroids.
Corticosteroids should be used cautiously in patients with ocular herpes simplex because of possible corneal perforation.
Administration of live virus vaccines is contraindicated in individuals receiving immunosuppressive doses of corticosteroids (see Section 4.3 Contraindications).
Long-term treatment should not be abruptly discontinued, as too rapid withdrawal may lead to drug induced secondary adrenocortical insufficiency. This may be minimised by gradual dosage reduction. This type of relative insufficiency may persist for months after therapy is discontinued. Therefore, in any situation of stress occurring in that period (such as anaesthesia, surgery or trauma) corticosteroid doses may need to be increased or the therapy reinstituted. Following prolonged therapy, withdrawal of corticosteroids may result in symptoms of the corticosteroid withdrawal syndrome including fever, myalgia, arthralgia, rhinitis, conjunctivitis, painful itchy skin nodules, loss of weight and and malaise.
Dexamethasone should be used only with extreme caution and frequent monitoring necessary in patients with diabetes mellitus or in those with:
diabetes mellitus or a family history of diabetes;
infectious diseases;
congestive heart failure or recent myocardial infarction;
chronic renal failure;
diverticulitis;
hypertension;
keratitis;
epilepsy and/or seizure disorder, migraine;
non-specific ulcerative colitis (if there is a probability of impending perforation, abscess or other pyogenic infection), fresh intestinal anastomoses, active or latent peptic ulcer;
osteoporosis, myasthenia gravis or in elderly persons.
Corticosteroids may cause reactivation of latent amoebiasis. Prior to treatment, amoebiasis should be ruled out in any patient with unexplained diarrhoea or who has recently spent time in the tropics.
Corticosteroids should be used with caution in patients who have had a recent cardiac infarction, as there have been reports of an apparent association between the use of corticosteroids and left ventricular free wall rupture in these patients; in patients with a history of severe affective disorders particularly of steroid induced psychoses; patients with previous steroid myopathy, liver failure, renal insufficiency, glaucoma (or family history of glaucoma); patients with thromboembolic disorders; patients with Duchenne's muscular dystrophy since transient rhabdomyolysis and myoglobinuria have been reported following strenuous physical activity; Cushing's disease; incomplete statural growth since glucocorticoids on prolonged administration may accelerate epiphyseal closure. Corticosteroids show an enhanced effect in patients with hypothyroidism or cirrhosis.
There is a lack of evidence to support the prolonged use of corticosteroids in septic shock. Although they may be of value in the early treatment, the overall survival may not be influenced.
Intra-articular injection of corticosteroids may produce systemic as well as local effects. Appropriate examination of any joint fluid present is necessary to exclude a septic process. A marked increase in pain, accompanied by local swelling, further restriction of joint motion, fever and malaise are suggestive of septic arthritis. If this complication occurs and sepsis is confirmed, appropriate antimicrobial therapy should be commenced.
Local injection of a steroid into an infected site is to be avoided. Corticosteroids should not be injected into unstable joints.
Frequent intra-articular injection may result in damage to joint tissues. Patients should be advised strongly of the importance of not overusing joints in which symptomatic benefit has been obtained as long as the inflammatory process remains active.
In the treatment of conditions such as tendinitis or tenosynovitis, care should be taken to inject into the space between the tendon sheath and the tendon as cases of ruptured tendon have been reported.
Intraarticular corticosteroids are associated with a substantially increased risk of an inflammatory response in the joint, particularly if a bacterial infection is introduced with the injection. Great care is required and all intraarticular corticosteroid injections should be undertaken in an aseptic environment.
Severe anaphylactoid reactions have occurred after administration of parenteral corticosteroids. Glottis oedema, urticaria and bronchospasm, have occasionally occurred, particularly in patients with history of allergy. Appropriate precautions should be taken prior to administration. If such an anaphylactoid reaction occurs, the following measures are recommended: immediate slow intravenous injection of adrenaline (epinephrine), intravenous administration of aminophylline, and artificial respiration if necessary.
Corticosteroids should not be used for the management of head injury or stroke because it is unlikely to be of any benefit and may even be harmful.
The results of a randomised, placebo-controlled study suggest an increase in mortality if methylprednisolone therapy starts more than two weeks after the onset of acute respiratory distress syndrome (ARDS). Therefore, treatment of ARDS with corticosteroids should be initiated within the first two weeks of onset of ARDS.
The slower rate of absorption after intramuscular injection should be noted.

Adrenocortical insufficiency.

Pharmacologic doses of corticosteroids administered for prolonged periods may result in hypothalamic-pituitary-adrenal (HPA) suppression (secondary adrenocortical insufficiency). The degree and duration of adrenocortical insufficiency produced is variable among patients and depends on the dose, frequency, time of administration and duration of therapy.
Symptoms of adrenal insufficiency include: malaise, muscle weakness, mental changes, muscle and joint pain, desquamation of the skin, dyspnoea, anorexia, nausea and vomiting, fever, hypoglycaemia, hypotension and dehydration.
During prolonged courses of corticosteroid therapy, sodium intake may need to be reduced and calcium and potassium supplements may be necessary. Monitoring of fluid intake and output and daily weight records may give an early warning of fluid retention.
Acute adrenal insufficiency leading to a fatal outcome may occur if glucocorticoids are withdrawn abruptly, therefore withdrawal of corticosteroids should always be gradual. A degree of adrenal insufficiency may persist for 6 to 12 months; therefore, in any situation of stress occurring during that period, steroid therapy may need to be reinstated. Since mineralocorticoid secretion may be impaired, treatment with salt and/or a mineralocorticoid may also be needed.

Anti-inflammatory/immunosuppressive effects and infection.

Suppression of the inflammatory response and immune function increases susceptibility to or mask the symptoms of infections, and their severity, and therefore should be used with caution in patients with systemic infections.
Immunosuppression is most likely to occur in patients receiving longer term; high dose systemic corticosteroid treatment, however, patients receiving moderate doses for short periods, or low doses over a prolonged period, may also be at risk.
Corticosteroids should be administered with caution to patients with latent tuberculosis or tuberculin reactivity, as reactivation of the disease may occur. These patients should, therefore, undergo chemoprophylaxis during prolonged corticosteroid therapy.
The clinical presentation may often be atypical and serious infections such as septicaemia and tuberculosis may be masked and may reach an advanced stage before being recognised when corticosteroids are used. The immunosuppressive effects of glucocorticoids may result in activation of latent infection or exacerbation of intercurrent infections.
Chicken pox is of particular concern, since this may be fatal in immunosuppressed patients. Patients without a definite history of chicken pox should be advised to avoid close personal contact with chicken pox or herpes zoster and if exposed they should seek urgent medical attention. If a diagnosis of chicken pox is confirmed the illness warrants specialist care and urgent treatment.
Patients should be advised to take particular care to avoid exposure to measles and to seek immediate medical advice if exposure occurs; prophylaxis with intramuscular normal immunoglobin may be needed.
Appropriate antimicrobial therapy should accompany glucocorticoid therapy when necessary e.g. in tuberculosis and viral and fungal infections of the eye.
Live vaccines are contraindicated in individuals on high doses or immunosuppressive doses of corticosteroids and should be postponed until at least 3 months after stopping corticosteroid therapy (see Section 4.3 Contraindications). The antibody response to other vaccines may be diminished. If inactivated viral or bacterial vaccines are administered to patients receiving immunosuppressive doses of corticosteroids, the expected serum antibody response may not be obtained. However, immunisation procedures may be undertaken in patients who are receiving corticosteroids as replacement therapy, e.g. for Addison's disease.

Visual disturbance.

Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.
Prolonged use of corticosteroids may produce subcapsular cataracts and nuclear cataracts (particularly in children), exophthalmos or increased intraocular pressure, which may result in glaucoma with possible damage to the optic nerves.
Corticosteroids should only be initiated in patients with ocular herpes simplex with appropriate viral cover by ophthalmologists because of the risk of corneal scaring loss of vision and corneal perforation.

Psychiatric effects.

Patients and/or carers should be warned that potentially severe psychiatric reactions may occur. Symptoms typically emerge within a few days or weeks of starting treatment. Most reactions resolve after either dose reduction or withdrawal, although specific treatment may be necessary. Patients and/or carers should be encouraged to seek medical advice if worrying psychological symptoms develop, especially if depressed mood or suicidal ideation is suspected.
Particular care is required when considering the use of corticosteroids in patients with existing or previous history of severe affective disorders in themselves or in the first-degree relatives. These would include depressive or manic-depressive illness and previous steroid psychosis.
Psychic derangements range from euphoria, insomnia, mood swings, personality changes and severe depression to frank psychotic manifestations.
Patients/carers should also be alert to possible psychiatric disturbances that may occur either during or immediately after dose tapering/withdrawal of systemic steroids, although such interactions have been reported infrequently.

Pheochromocytoma crisis.

Pheochromocytoma crisis, which can be fatal, has been reported after administration of systemic corticosteroids. Corticosteroids should only be administered to patients with suspected or identified pheochromocytoma after an appropriate risk/benefit evaluation.

Use in the elderly.

Geriatric patients may be more likely to develop hypertension and osteoporosis as a result of corticosteroid therapy.
Long-term use in the elderly should be planned bearing in mind the more serious consequences of the common side-effects of corticosteroids in old age, especially osteoporosis, diabetes, hypertension, hypokalaemia, susceptibility to infection and thinning of the skin. Close medical supervision is required to avoid life-threatening reactions.

Paediatric use.

Corticosteroids cause growth retardation in infancy, childhood and adolescence, which may be irreversible and therefore long-term administration of pharmacological doses should be avoided. If prolonged therapy is necessary, treatment should be limited to the minimum suppression of the hypothalamic-pituitary adrenal axis and growth retardation, the growth and development of infants and children should be closely monitored. Treatment should be limited, where possible, to a single dose on alternate days.
Children are at special risk from raised intracranial pressure.

Hypertrophic cardiomyopathy.

Hypertrophic cardiomyopathy was reported after systemic administration of corticosteroids including dexamethasone to prematurely born infants, therefore appropriate diagnostic evaluation and monitoring of cardiac function and structure should be performed (see Section 4.8 Adverse Effects (Undesirable Effects)). In the majority of cases reported, this was reversible on withdrawal of treatment.

Effects on laboratory tests.

Dexamethasone suppression tests may be affected by drugs which enhance the metabolic clearance of corticosteroids (see Section 4.5 Interactions with Other Medicines and Other Forms of Interactions).
False negative results in the dexamethasone suppression test have been reported in patients being treated with indomethacin or high doses of benzodiazepines or cyproheptadine.
Corticosteroids have been reported to alter the response to anticoagulant agents (see Section 4.5 Interactions with Other Medicines and Other Forms of Interactions). The prothrombin time should be checked frequently in patients receiving these combinations.
Corticosteroids may affect a wide range of diagnostic tests. They may affect brain and skeletal imaging using ⁹⁹Tc, by decreasing uptake of ⁹⁹Tc into cerebral tumours or bone, respectively, and may decrease ¹²³I and ¹³¹I uptake into the thyroid. Corticosteroids may alter the results of the gonadorelin test for hypothalamic-pituitary-gonadal axis function, affect thyroid function test results, and suppress skin test reactions including tuberculin and histoplasmin skin tests and patch tests for allergy. Corticosteroids may also affect the nitroblue tetrazolium test for bacterial infection and produce false negative results.

4.5 Interactions with Other Medicines and Other Forms of Interactions

Medicines that induce hepatic enzyme cytochrome P450 isoenzyme 3A4 such as barbiturates, phenylbutazone, phenobarbital (phenobarbitone), phenytoin or rifampicin, rifabutin, carbamazepine, primidone and aminoglutethimide may increase the metabolism and thus reduce the effects of corticosteroids. Ephedrine and aminoglutethimide may also increase dexamethasone metabolism.
Medicines that inhibit hepatic enzyme cytochrome P450 isoenzyme 3A4 such as ketoconazole, ciclosporin or ritonavir may decrease glucocorticoid clearance. A reduction in corticosteroid dose may be needed to reduce the risk of adverse effects.
Antithyroid agents, estrogens and other oral contraceptives may decrease hepatic metabolism and thus increase the effects of corticosteroids. The dose of corticosteroid may need to be adjusted if estrogen therapy is commenced or stopped.
The effects of anticholinesterases are antagonised by corticosteroids in myasthenia gravis.
The effects of anticoagulant agents are usually decreased (but may be increased in some patients) if corticosteroids are administered concurrently. Close monitoring of the INR or prothrombin time is required to avoid spontaneous bleeding.
Seizures have reportedly occurred in adult and paediatric patients receiving high dose corticosteroid therapy concurrently with ciclosporin.
Concurrent administration of dexamethasone with anticoagulants, heparin, streptokinase, urokinase, alcohol or non-steroidal anti-inflammatory drugs (NSAIDs) including aspirin may increase the risk of gastrointestinal ulceration or haemorrhage. Salicylates should be used cautiously in conjunction with corticosteroid in patients with hypoprothrombinaemia. The renal clearance of salicylates is increased by corticosteroids and steroid withdrawal may result in salicylate intoxication. Patients should be observed closely for adverse effects of either medicine.
Co-treatment with CYP3A inhibitors, including cobicistat-containing products, is expected to increase the risk of systemic side effects. The combination should be avoided unless the benefit outweighs the increased risk of systemic corticosteroid side-effects, in which case patients should be monitored for systemic corticosteroid effects.
Diuretics, hypoglycaemic agents (including insulin), and cardiac glycosides are antagonised by corticosteroids and the hypokalaemic effects of acetazolamide, loop diuretics, thiazide diuretics and carbenoxolone are enhanced.
Potassium loss may occur as a result of dexamethasone administration (see Section 4.8 Adverse Effects (Undesirable Effects)). Concurrent administration of corticosteroids with potassium depleting diuretics (such as thiazides, furosemide (frusemide) or etacrynic acid), carbonic anhydrase inhibitors (such as acetazolamide) or amphotericin B (amphotericin) may result in severe hypokalaemia. The activity of digitalis glycosides and nondepolarising neuromuscular blocking agents may be potentiated as a result of glucocorticoid induced hypokalaemia. The efficacy of potassium supplements and potassium sparing diuretics on serum potassium concentrations may be reduced by concurrent corticosteroid administration. Monitoring of serum potassium concentration is therefore recommended.
Glucocorticoids may increase blood glucose concentrations. Dosage adjustment of asparaginase (colaspase) and of antidiabetic agents such as sulfonylureas and insulins may be necessary.
The growth promoting effect of somatropin may be inhibited.
There is an increased risk of hypokalaemia if high doses of corticosteroids are given with high doses of salbutamol, salmeterol, terbutaline or formoterol (formoterol).
Concurrent use of antacids may decrease absorption of corticosteroids - efficacy may be decreased sufficiently to require dosage adjustments in patients receiving small doses of corticosteroids.

4.6 Fertility, Pregnancy and Lactation

Effects on fertility.

Corticosteroids may increase or decrease the motility and number of spermatozoa in some patients.
(Category C)
The ability of corticosteroids to cross the placenta varies between individual drugs, however, dexamethasone readily crosses the placenta. Studies have shown an increased risk of neonatal hypoglycaemia following antenatal administration of a short course of corticosteroids including dexamethasone to women at risk for late preterm delivery.
In animal experiments, corticosteroids have been found to cause malformations of various kinds (cleft palate, skeletal malformations). These findings do not seem to be relevant to humans. Reduced placental and birthweight have been recorded in animals and humans after long-term treatment. Since the possibility of suppression of the adrenal cortex in the newborn baby after long-term treatment must be considered, the needs of the mother must be carefully weighed against the risk to the fetus when prescribing corticosteroids. However, the short-term use of antepartum corticosteroids for the prevention of respiratory distress syndrome, when warranted, does not seem to pose a risk.
There is evidence of harmful effects on pregnancy in animals. Infants born to mothers who have received substantial doses of corticosteroids during the pregnancy should be carefully observed, for signs of adrenal insufficiency.
Patients with pre-eclampsia or fluid retention require close monitoring.
Corticosteroids appear in breast milk and could suppress growth, interfere with endogenous corticosteroid production or cause other unwanted effects in breastfed infants. Women taking corticosteroids should be advised not to breastfeed.
Infants of mothers taking high doses of systemic corticosteroids for prolonged periods may have a degree of adrenal suppression. Suppression of growth or other adverse effects may occur.

4.7 Effects on Ability to Drive and Use Machines

The effects of this medicine on a person's ability to drive and use machines were not assessed as part of its registration. However, adverse effects of Dexamethasone Viatris include dizziness, drowsiness, insomnia, convulsions, vertigo and blurred vision which could affect the ability to drive or use machines (see Section 4.8 Adverse Effects (Undesirable Effects)).

4.8 Adverse Effects (Undesirable Effects)

The following adverse reactions have been reported with dexamethasone therapy. Except for allergic reactions, the adverse effects listed have been associated with prolonged therapy and/or high doses.

Endocrine disorders.

Adrenal suppression, menstrual irregularities, amenorrhoea, development of Cushingoid state, weight gain secondary adrenocortical and pituitary unresponsiveness particularly in times of stress (e.g. trauma, surgery or illness), decreased carbohydrate tolerance, increased requirements for insulin or oral hypoglycaemic agents in diabetes, development of diabetes mellitus, hyperglycaemia, hirsutism, growth suppression in infancy, childhood and adolescence, increased appetite.

Cardiovascular disorders.

Thromboembolism, hypertension, polymorphonuclear leucocytosis, neuropathy, vasculitis, impaired myocardial contractility (prolonged treatment), congestive heart failure in susceptible patients, myocardial rupture following recent cardiac infarction, hypertrophic cardiomyopathy in low birthweight and prematurely born infants (see Section 4.4 Special Warnings and Precautions for Use).

Musculoskeletal and connective tissue disorders.

Proximal myopathy, osteoporosis, arthropathy, Charcot-like arthropathy following intra-articular injection, premature epiphyseal closure, muscle atrophy, muscle weakness, steroid myopathy, vertebral compression, aseptic necrosis of femoral and humeral heads, avascular osteonecrosis, myalgia, growth suppression in infancy, childhood and adolescence., tendon rupture, myalgia. These may occur as a result of protein catabolism associated with prolonged glucocorticoid therapy.

Eye disorders.

Increased intraocular pressure, glaucoma, papilloedema, posterior subcapsular cataracts, or increased intraocular pressure may lead to glaucoma or occasionally damage to the optic nerve, cataracts, vision blurred, exophthalmos, corneal or scleral thinning, retinopathy of prematurity, enhanced establishment of secondary fungal and viral eye infections, chorioretinopathy, blurred vision, blindness associated with intralesional therapy around the face and neck.

Reproductive system and breast disorders.

A transient burning or tingling sensation mainly in the perineal area following intravenous injection of large doses of corticosteroid phosphates, menstrual irregularities and amenorrhoea.

Skin and subcutaneous tissue disorders.

Hirsutism, skin atrophy - subcutaneous and cutaneous atrophy, allergic dermatitis, urticaria, erythema, thin fragile skin, telangiectasia, petechiae and ecchymoses, increased sweating, may suppress skin test reactions, angioneurotic oedema, acne, striae, sterile abscess, hyperpigmentation or hypopigmentation, candidiasis.

Blood and lymphatic system disorders.

Diminished lymphoid tissue and leucocytosis.

Injury, poisoning, and procedural complications.

Easy bruising, tendon rupture and pathological fracture of long bones.

Infections and infestations.

Increased susceptibility to and severity of infections with suppression of clinical symptoms and signs, opportunistic infections, candidiasis, recurrence of dormant tuberculosis. Glucocorticoids, especially in large doses, increase susceptibility to infection, and may mask the symptoms of infection (see Section 4.4 Special Warnings and Precautions for Use).

Immune system disorders.

Diminished immune response, decrease responsiveness to vaccination. Hypersensitivity including anaphylaxis has been reported.

Gastrointestinal disorders.

Dyspepsia, nausea, peptic ulcer with possible perforation and haemorrhage, abdominal distension, abdominal pain, diarrhoea, acute pancreatitis, perforation of the small or large bowel particularly in patients with inflammatory bowel disease, abdominal distension, ulcerative oesophagitis, oesophageal candidiasis, nausea.

Nervous system disorders.

Dizziness, headache, burning and tingling, convulsions, increased intracranial pressure with papilloedema, labile mood. Aggravation of epilepsy, behavioural disturbances, sleep disturbances, cognitive dysfunction, amnesia.

Ear and labyrinth disorders.

Vertigo.

Psychiatric disorders.

Affective disorders (such as irritable, euphoric, depression, and suicidal thoughts), psychotic reactions (including mania, delusions, hallucinations, and aggravation of schizophrenia), irritability, anxiety, confusion, psychological dependence, mental disturbances, insomnia.

Fluid and electrolyte disturbances.

Electrolyte imbalance (retention of sodium and water with oedema and hypertension), potassium loss, hypokalaemic alkalosis, hypocalcaemia, increased calcium and potassium excretion.

Metabolic and nutrition disorders.

Nitrogen depletion, negative nitrogen and calcium balance due to protein catabolism, negative protein/nitrogen and calcium balance, decreased carbohydrate tolerance, increased requirements for insulin or oral hypoglycaemic agents in diabetes, development of diabetes mellitus, hyperglycaemia, weight gain, increased appetite.

Other effects.

Allergic reactions, fatigue, malaise, hiccups.
The incidence of predictable undesirable effects, including hypothalamic-pituitary-adrenal suppression correlates with the relative potency of the drug, dosage, timing of administration and the duration of treatment.

Reporting suspected adverse effects.

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 Overdose

Symptoms.

It is difficult to define an excessive dose of a corticosteroid as the therapeutic dose will vary according to the indication and patient requirements. High dose corticosteroids given as recommended for pulse therapy are relatively free from hazardous effects.
Reports of acute toxicity and/or deaths following overdosage with glucocorticoids are rare. Exaggeration of corticosteroid related adverse effects may occur including hypertension, oedema, peptic ulceration, hyperglycaemia and altered mental state. Anaphylactic or hypersensitivity reactions may occur.

Treatment.

No antidote is available. Treatment of overdosage is symptomatic. The dosage should be reduced, or the drug withdrawn. Anaphylactic and hypersensitivity reactions may be treated with adrenaline (epinephrine), positive pressure artificial respiration and aminophylline. The patient should be kept warm and quiet.
For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Mechanism of action.

Dexamethasone is a synthetic adrenocorticosteroid with glucocorticoid activity. It is one of the most active glucocorticoids, being about 25 to 30 times as potent as hydrocortisone. Unlike hydrocortisone, dexamethasone has little if any mineralocorticoid activity.
Dexamethasone has anti-inflammatory and immunosuppressant activity. Glucocorticoids prevent the development of the inflammatory response, i.e. redness, swelling, tenderness. They also inhibit capillary dilation and phagocytosis and appear to prevent the hypersensitivity responses which occur after antigen-antibody reactions.
The principal metabolic actions of dexamethasone are on gluconeogenesis, glycogen deposition and protein and calcium metabolism. Dexamethasone also influences the mobilisation, oxidation, synthesis and storage of fats.
Dexamethasone suppresses the release of adrenocorticotrophic hormone (ACTH) from the pituitary, resulting in inhibition of endogenous corticotrophin secretion.
Except for its use in the treatment of adrenal insufficiency, dexamethasone does not cure disease. Rather, the anti-inflammatory and immunosuppressant actions of dexamethasone suppress the symptoms associated with the disease.

Clinical trials.

No data available.

5.2 Pharmacokinetic Properties

Absorption.

Dexamethasone sodium phosphate is absorbed rapidly following intramuscular or intravenous injection.
Intramuscular injections of dexamethasone phosphate give maximum plasma concentrations of dexamethasone at one hour.
The biological half-life of dexamethasone is about 190 minutes.

Distribution.

In the circulation, small amounts of dexamethasone are bound to plasma proteins.

Metabolism.

Synthetic corticosteroids such as dexamethasone are less extensively protein bound and more slowly metabolised than hydrocortisone. Dexamethasone penetrates into tissue fluids and cerebrospinal fluids. Metabolism occurs in most tissues, but primarily in the liver.

Excretion.

The inactive metabolites are excreted in the urine, mainly as glucuronides and sulfates but also as unconjugated metabolites. Small amounts of unchanged drug are also excreted in the urine. Up to 65% of a dose of dexamethasone is excreted in the urine within 24 hours.

5.3 Preclinical Safety Data

Genotoxicity.

No data available.

Carcinogenicity.

No data available.

6 Pharmaceutical Particulars

6.1 List of Excipients

Sodium citrate, creatinine and water for injections.

6.2 Incompatibilities

Dexamethasone sodium phosphate is physically incompatible with daunorubicin, doxorubicin and vancomycin and should not be admixed with solutions containing these drugs. Dexamethasone sodium phosphate is also incompatible with doxapram HCl and glycopyrrolate in syringe.

6.3 Shelf Life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 Special Precautions for Storage

Store below 25°C. Protect from light.

6.5 Nature and Contents of Container

Dexamethasone Viatris is supplied in a type 1 amber glass vial with a chlorobutyl rubber stopper and aluminium flip-off seal.
Pack sizes: 5 vials, 10 vials.
Some strengths, pack sizes and/or pack types may not be marketed.

Australian register of therapeutic goods (ARTG).

AUST R 163199 - Dexamethasone Viatris dexamethasone phosphate (as dexamethasone sodium phosphate) 8 mg/2 mL solution for injection.
AUST R 163200 - Dexamethasone Viatris dexamethasone phosphate (as dexamethasone sodium phosphate) 4 mg/1 mL solution for injection.

6.6 Special Precautions for Disposal

In Australia, any unused medicine or waste material should be disposed of in accordance with local requirements.

6.7 Physicochemical Properties

Chemical structure.

Chemical name: 9-fluoro-11β,17-dihydroxy-16α-methyl-3,20-dioxopregna-1,4-dien-21-yl disodium phosphate.
Molecular formula: C₂₂H₂₈FNa₂O₈P.
Molecular weight: 516.4.
Dexamethasone sodium phosphate is a white or slightly yellow, very hygroscopic, crystalline powder. It is odourless or has a slight odour of alcohol. Dexamethasone sodium phosphate is freely soluble in water, slightly soluble in alcohol, practically insoluble in chloroform and ether and very slightly soluble in 1,4-dioxane.
The pH of a 1% solution in water is between 7.5 and 9.5.

CAS number.

2392-39-4.

7 Medicine Schedule (Poisons Standard)

S4 (Prescription Only Medicine).

Log in

Consumer medicine information

Dexamethasone Viatris

Dexamethasone phosphate

Keep track of your medicines

BRAND INFORMATION